IMUXInvestor•prnewswire•
Immunic to Participate in Investor and Scientific Conferences in September
Sentiment:Negative (30)
Summary
(NASDAQ:IMUX) NEW YORK, Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 4, 2025 by prnewswire